Literature DB >> 25016597

Diets that differ in their FODMAP content alter the colonic luminal microenvironment.

Emma P Halmos1, Claus T Christophersen2, Anthony R Bird2, Susan J Shepherd3, Peter R Gibson1, Jane G Muir1.   

Abstract

OBJECTIVE: A low FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) diet reduces symptoms of IBS, but reduction of potential prebiotic and fermentative effects might adversely affect the colonic microenvironment. The effects of a low FODMAP diet with a typical Australian diet on biomarkers of colonic health were compared in a single-blinded, randomised, cross-over trial.
DESIGN: Twenty-seven IBS and six healthy subjects were randomly allocated one of two 21-day provided diets, differing only in FODMAP content (mean (95% CI) low 3.05 (1.86 to 4.25) g/day vs Australian 23.7 (16.9 to 30.6) g/day), and then crossed over to the other diet with ≥21-day washout period. Faeces passed over a 5-day run-in on their habitual diet and from day 17 to day 21 of the interventional diets were pooled, and pH, short-chain fatty acid concentrations and bacterial abundance and diversity were assessed.
RESULTS: Faecal indices were similar in IBS and healthy subjects during habitual diets. The low FODMAP diet was associated with higher faecal pH (7.37 (7.23 to 7.51) vs. 7.16 (7.02 to 7.30); p=0.001), similar short-chain fatty acid concentrations, greater microbial diversity and reduced total bacterial abundance (9.63 (9.53 to 9.73) vs. 9.83 (9.72 to 9.93) log10 copies/g; p<0.001) compared with the Australian diet. To indicate direction of change, in comparison with the habitual diet the low FODMAP diet reduced total bacterial abundance and the typical Australian diet increased relative abundance for butyrate-producing Clostridium cluster XIVa (median ratio 6.62; p<0.001) and mucus-associated Akkermansia muciniphila (19.3; p<0.001), and reduced Ruminococcus torques.
CONCLUSIONS: Diets differing in FODMAP content have marked effects on gut microbiota composition. The implications of long-term reduction of intake of FODMAPs require elucidation. TRIAL REGISTRATION NUMBER: ACTRN12612001185853. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  BIFIDOBACTERIA; BUTYRATE; SHORT CHAIN FATTY ACIDS

Mesh:

Substances:

Year:  2014        PMID: 25016597     DOI: 10.1136/gutjnl-2014-307264

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  178 in total

Review 1.  The gut microbiome in health and in disease.

Authors:  Andrew B Shreiner; John Y Kao; Vincent B Young
Journal:  Curr Opin Gastroenterol       Date:  2015-01       Impact factor: 3.287

2.  Comparison of gut microbiota profile in celiac disease, non-celiac gluten sensitivity and irritable bowel syndrome: A systematic review.

Authors:  Elin Lund Transeth; Hanna Fjeldheim Dale; Gülen Arslan Lied
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

Review 3.  A Systematic Review of the Effects of Polyols on Gastrointestinal Health and Irritable Bowel Syndrome.

Authors:  Adrienne Lenhart; William D Chey
Journal:  Adv Nutr       Date:  2017-07-14       Impact factor: 8.701

4.  Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome.

Authors:  Jørgen Valeur; Milada Cvancarova Småstuen; Torunn Knudsen; Gülen Arslan Lied; Arne Gustav Røseth
Journal:  Dig Dis Sci       Date:  2018-01-04       Impact factor: 3.199

Review 5.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

6.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

7.  The gastrointestinal tract microbiome, probiotics, and mood.

Authors:  Luis Vitetta; Matthew Bambling; Hollie Alford
Journal:  Inflammopharmacology       Date:  2014-09-30       Impact factor: 4.473

Review 8.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

9.  Bioelectrical impedance vector analysis in patients with irritable bowel syndrome on a low FODMAP diet: a pilot study.

Authors:  M Bellini; D Gambaccini; L Bazzichi; G Bassotti; M G Mumolo; B Fani; F Costa; A Ricchiuti; N De Bortoli; M Mosca; S Marchi; A Rossi
Journal:  Tech Coloproctol       Date:  2017-05-31       Impact factor: 3.781

Review 10.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.